Opthea Updates on Phase I and II OPT-302 Trials

Opthea CEO & Managing Director Megan Baldwin, PhD, updates the status of Phase I and II dose-escalation studies of the company’s lead agent OPT-302 in combination with ranibizumab (Lucentis) for treatment of neovascular age-related macular degeneration and diabetic macular edema. At OIS@ASRS 2017, she explains how OPT-302 blocks the VEGF-C and D signaling pathways that existing anti-VEGF treatments do not target.

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.